Tauriga Sciences, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by SHAW SETH M, was filed 27 May 2021.
Tauriga Sciences, Inc.: what insiders have been doing
Every trade that managers of Tauriga Sciences, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. No insider at Tauriga Sciences, Inc. has published a filing in the past twelve months. The most recent one dates from 27 May 2021.
The full history, which starts in 2012, counts 39 purchases against 17 sales.
This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2021FY ended March 2021 · cache
- 250,000 sharesCommon Stock, par value $0.00001SEC:0001493152-21-013045:0Canonical exit: 25 Aug 2021 (T+90)
- 700,000 sharesCommon Stock, par value $0.00001SEC:0001493152-20-013088:0Canonical exit: 8 Oct 2020 (T+90)
- 110,000,000 sharesCommon Stock, par value $0.00001SEC:0001493152-17-011389:0Canonical exit: 4 Jan 2018 (T+90)
- 44,000,000 sharesCommon Stock, par value $0.00001SEC:0001493152-17-006988:0Canonical exit: 19 Sept 2017 (T+90)
- 76,000,000 sharesCommon Stock, par value $0.00001SEC:0001493152-17-006740:0Canonical exit: 13 Sept 2017 (T+90)
- 600,000 shares@ US$0.003765.4% of flowCommon Stock, par value $0.00001SEC:0001493152-16-013347:0
- 72,500 shares@ US$0.008919.3% of flowCommon Stock, par value $0.00001SEC:0001493152-16-011473:0
- 8,000,000 shares0Common Stock, par value $0.00001SEC:0001493152-16-009122:1
- 8,000,000 shares0Common Stock, par value $0.00001SEC:0001493152-16-009123:0
- 37,500,000 shares0Common Stock, par value $0.00001SEC:0001493152-16-009124:0
- 169,700 shares@ US$0.00315.2% of flowCommon Stock, par value $0.00001SEC:0001493152-16-009122:0
- 137,300 shares@ US$0.0027Common Stock, par value $0.001SEC:0001493152-15-006173:0
- 247,000 shares@ US$0.0042Common Stock, par value $0.001SEC:0001493152-15-005259:0
- 800,000 shares@ US$0.0118Common Stock, par value $0.001SEC:0001493152-15-001018:0Canonical exit: 21 Jun 2015 (T+90)
- 2,695,850 shares@ US$0.016Common StockSEC:0001493152-14-004046:1
- 804,150 shares@ US$0.0154Common StockSEC:0001493152-14-004046:2
- 3,500,000 shares@ US$0.0152Common StockSEC:0001493152-14-003636:1
- 1,440,000 shares@ US$0.0125Common Stock, par value $0.001SEC:0001493152-14-003242:0Canonical exit: 5 Jan 2015 (T+90)
- 1,781,000 shares@ US$0.0288Common StockSEC:0001144204-14-049005:0
- 1,719,000 shares@ US$0.0266Common StockSEC:0001144204-14-049005:1
- 3,500,000 shares@ US$0.0419Common StockSEC:0001144204-14-044276:0
- 75,000,000 shares@ US$0.026Common StockSEC:0001144204-14-042133:0
- 59,414,991 shares@ US$0.0328Common StockSEC:0001144204-14-042133:1
- 200,000 shares@ US$0.024Common Stock, par value $0.001SEC:0001493152-14-002020:0Canonical exit: 22 Sept 2014 (T+90)
- 3,500,000 shares0Common StockSEC:0001144204-14-027418:0
25 of 68 declarations
About Tauriga Sciences, Inc.
Tauriga Sciences, Inc. is a United States-based micro-cap life sciences company whose public reporting and legacy disclosures place it in the broad Health & Pharma / consumer wellness universe. For investors, it is best understood as a small, speculative commercial-development platform rather than a conventional large-scale pharmaceutical issuer. The company was founded in 2003 and has evolved over time from an earlier corporate structure into a business focused on proprietary products, brand development, and selective acquisition or licensing opportunities. Tauriga has described itself in SEC filings as operating in the life sciences technology and consumer-products space, with headquarters history that includes Danbury, Connecticut, Midtown Manhattan in New York City, and later Wappingers Falls, New York. It is a United States company, and for market-reference purposes it is discussed in the context of the U.S. listed-company universe tied to NYSE/NASDAQ-style public-market coverage, although the business has historically been associated with the OTC environment.
The company’s main commercial theme has been product development, distribution, and licensing. Its best-known brand is Tauri-Gum™, a proprietary chewing-gum platform that has been marketed in CBD and CBG-infused versions, along with other functional formulations and limited-edition flavors. SEC materials also reference adjacent product concepts and a pharmaceutical-development initiative centered on a more advanced, potentially prescription-oriented version of Tauri-Gum. In practice, this means Tauriga has tried to combine consumer wellness branding with a longer-term optionality in pharma-style development. The company has also used subsidiaries and corporate reorganization to support those aims, while continuing to evaluate acquisition candidates and other revenue opportunities.
Read moreShow less
From a competitive standpoint, Tauriga does not appear to compete head-to-head with large-cap pharmaceutical leaders. Instead, it operates in niche categories where differentiation, brand recognition, formulation IP, and channel access matter more than scale. That leaves the company exposed to meaningful execution risk, regulatory uncertainty, and financing dependence, but it also creates upside if a product line gains traction. Historically, its commercial emphasis has been on the New York metropolitan area and broader Northeast U.S. distribution, supported by e-commerce and selective retail pathways.
Recent public disclosures suggest a continued focus on CBD/CBG consumer products, online commercialization, and pharmaceutical development initiatives, alongside the normal capital-markets constraints that affect micro-cap issuers. For French, Belgian, and Swiss investors, the key takeaway is that Tauriga Sciences is a high-risk, low-visibility U.S. listed health-and-wellness story with changing strategic priorities, limited scale, and a strong dependence on product execution and financing discipline. Any analysis should therefore emphasize corporate flexibility, dilution risk, and the uncertainty of future commercial adoption rather than assuming stable operating momentum.
